Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 19/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 14/20 | 1.00 |
| ▸ | PDE2A | O00408 | 6/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.82 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.82 |
| ▸ | PTGFR | P43088 | 1/20 | 0.82 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.82 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.82 |
| ▸ | PTGIR | P43119 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5824247 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL20531411 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL1255195 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL6521839 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL1043387 | 0.95 | PTGDR (0.90) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL20531485 | 0.95 | PTGDR (0.90) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL5421906 | 0.95 | PTGDR (0.90) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL990414 | 0.95 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL6097496 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 | |
| SCHEMBL989833 | 0.92 | PTGDR (1.00) | PTGDRTBXA2RPDE2APTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | MERCK FROSST CANADA & CO. (CA) | 2007-03-08 | — | — | US | claimed |
| US-12589089-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20250017900-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | UNIVERSITÉ PARIS CITÉ (FR) | 2025-01-16 | — | — | US | disclosed |
| EP-2116244-B1 | Method of treating atherosclerosis, dyslipidemias and related conditions | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| EP-2286816-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| EP-2116244-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | Merck & Co., Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090233977-A1 | Method of Treating Atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| EP-1809284-A4 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1809284-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | MERCK FROSST CANADA & CO. (CA) | 2007-03-08 | — | — | US | disclosed |
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | MERCK FROSST CANADA & CO. (CA) | 2007-03-08 | — | — | US | disclosed |
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | MERCK FROSST CANADA & CO. (CA) | 2007-03-08 | — | — | US | disclosed |
| WO-2006052555-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052798-A2 | METHOD OF TREATING PATHOLOGICAL BLUSHING | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-7019022-B2 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA & CO. (CA) | 2006-03-28 | — | — | US | disclosed |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA LTD. (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017900-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR, PTGDR2, PTGIR | PTGDR 1/4885TBXA2R 16/4885PDE2A 223/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | PTGDR 164/4885TBXA2R 44/4885PDE2A 813/4885 |
| US-20070054951-A1 | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists | PTGDR2, PTGER2, PTGDR | PTGDR 3/4885TBXA2R 18/4885PDE2A 295/4885 |
| US-20090233977-A1 | Method of Treating Atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PDE2A 1108/4885 |
| US-12589089-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | PTGIR, PTGDR, SSB | PTGDR 2/4885TBXA2R 13/4885PDE2A 346/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | PTGDR 97/4885TBXA2R 68/4885PDE2A 1070/4885 |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | PTGIR, PTGDR, PTGDR2 | PTGDR 2/4885TBXA2R 10/4885PDE2A 1080/4885 |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PDE2A 1108/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PDE2A 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.